Newsfeeds - Spark Newswire

2 minute read

Reported Late Monday March 13, Everest Medicines Announces Partner Calliditas Therapeutics Reports Topline Results From Phase 3 NefIgArd Trial Evaluating Nefecon In IgA Nephropathy; Trial Primary Endpoint Was Met With Nefecon

Today, 10:41 PM

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company") announced today that its partner Calliditas Therapeutics AB (NASDAQ:CALT, Nasdaq Stockholm: CALTX)))) ("Calliditas") reported

CALT

3 minute read

Nasdaq Up 150 Points; Gold Rises Over 2%

By Lisa Levin

Today, 10:41 PM

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 150 points on Monday. The Dow traded up 0.59% to 32,096.68 while the NASDAQ rose 1.35% to 11,288.8. The S&P 500, also rose, gaining, 0.78% 3,891.75.

BVH

4 minute read

Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

Today, 10:41 PM

Gainers Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash.

ARDS

3 minute read

US Stocks Mostly Higher; Dow Rises 75 Points

By Lisa Levin

Today, 10:41 PM

U.S. stocks traded mostly higher this morning, with the Dow Jones gaining around 75 points on Monday. Following the market opening Monday, the Dow traded up 0.24% to 31,986.55 while the NASDAQ rose 0.24% to 11,165.62. The S&P 500, meanwhile, fell, dropping, 0.03% to 3,860.50.

BVH

1 minute read

News

Calliditas Therapeutics Announced Primary Endpoint Successfully Met In Phase 3 NefIgArd Trial Evaluating Nefecon In IgA Nephropathy

By Charles Gross

Today, 10:41 PM

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced positive topline results from the global, randomized, double-blind, placebo-controlled Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon (TARPEYO®/Kinpeygo® (budesonide) delayed release capsules) versus placebo in patients with primary IgA nephropathy (IgAN).

CALT

1 minute read

Analyst Sits On Fence While Initiating Calliditas Citing ‘Near-Term Opportunity But Longer-Term Questions’

By Vandana Singh

Today, 10:41 PM

Guggenheim initiated coverage on Calliditas Therapeutics AB (NASDAQ:CALT) with a Neutral rating and an $18 price target. The analyst is impressed with…

CALT

1 minute read

Guggenheim Initiates Coverage On Calliditas Therapeutics with Neutral Rating, Announces Price Target of $18

By Benzinga Newsdesk

Today, 10:41 PM

Guggenheim analyst Vamil Divan initiates coverage on Calliditas Therapeutics (NASDAQ:CALT) with a Neutral rating and announces Price Target of $18.

CALT

1 minute read

Citigroup Maintains Buy on Calliditas Therapeutics, Raises Price Target to $79

By Benzinga Newsdesk

Today, 10:41 PM

Citigroup analyst Yigal Nochomovitz maintains Calliditas Therapeutics (NASDAQ:CALT) with a Buy and raises the price target from $76 to $79.

CALT

2 minute read

Comfort Systems, Gannett, CommScope And Other Big Stocks Moving Higher On Thursday

By Lisa Levin

Today, 10:41 PM

U.S. stocks traded slightly lower, with the Dow Jones dropping around 30 points on Thursday. Here are some big stocks recording gains in today’s session.

ACVA